Enanta Pharmaceuticals, Inc. (ENTA) Social Stream



Enanta Pharmaceuticals, Inc. (ENTA): $12.13

0.93 (-7.12%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ENTA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#105 of 362

in industry

Featured Post From StockTwits About ENTA

$ENTA New Press Release:

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for chronic HBV patients. “We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical st (...)

https://wchr.one/114238
WebChronicleToday, published August 16, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!